Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments. Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data. Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC. Cristina Suarez discusses the biggest RCC trials of 2023. Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting. Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC. Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023. Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy. Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania. Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting. Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma. Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered. Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023. The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD. Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC. Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease. Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer. The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx. A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.